TRAX
Income statement / Annual
Last year (2025), First Tracks Biotherapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, First Tracks Biotherapeutics Inc.'s net income was -$166.09 M.
See First Tracks Biotherapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$139.61 M
|
$152.35 M
|
$0.00
|
| Gross Profit |
-$139.61 M
|
-$152.35 M
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$139.61 M
|
$152.35 M
|
$97.59 M
|
| General & Administrative Expenses |
$39.39 M
|
$28.76 M
|
$20.87 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$39.39 M
|
$28.76 M
|
$20.87 M
|
| Other Expenses |
-$139.61 M
|
-$152.35 M
|
$0.00
|
| Operating Expenses |
$39.39 M
|
$28.76 M
|
$118.46 M
|
| Cost And Expenses |
$179.01 M
|
$181.10 M
|
$118.46 M
|
| Interest Income |
$0.00
|
$17.38 M
|
$12.31 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$559.00 K
|
$2.40 M
|
$2.38 M
|
| EBITDA |
-$178.45 M |
-$178.70 M |
-$116.09 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$12.92 M
|
$17.40 M
|
$12.31 M
|
| Income Before Tax |
-$166.09 M
|
-$163.71 M
|
-$106.15 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$166.09 M
|
-$163.71 M
|
-$106.15 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
0 |
0 |
-3.05 |
| EPS Diluted |
0 |
0 |
-3.05 |
| Weighted Average Shares Out |
$0.00
|
$0.00
|
$34.75 M
|
| Weighted Average Shares Out Diluted |
$0.00
|
$0.00
|
$34.75 M
|
| Link |
|
|
|
